162 related articles for article (PubMed ID: 17590285)
1. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States.
Cicero TJ; Inciardi JA; Surratt H
Drug Alcohol Depend; 2007 Dec; 91(2-3):115-20. PubMed ID: 17590285
[TBL] [Abstract][Full Text] [Related]
2. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
[TBL] [Abstract][Full Text] [Related]
3. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
4. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Cicero TJ; Surratt H; Inciardi JA; Munoz A
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
[TBL] [Abstract][Full Text] [Related]
5. Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: results of an abuse monitoring system, 1994-2004.
Cicero TJ; Inciardi JA; Adams EH; Geller A; Senay EC; Woody GE; Muñoz A
Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):851-9. PubMed ID: 15892169
[TBL] [Abstract][Full Text] [Related]
6. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007.
Schneider MF; Bailey JE; Cicero TJ; Dart RC; Inciardi JA; Parrino M; Muñoz A
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):778-90. PubMed ID: 19536784
[TBL] [Abstract][Full Text] [Related]
7. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
Cicero TJ; Inciardi JA; Muñoz A
J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids.
Manchikanti L; Singh A
Pain Physician; 2008 Mar; 11(2 Suppl):S63-88. PubMed ID: 18443641
[TBL] [Abstract][Full Text] [Related]
9. FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse.
Inciardi JA; Surratt HL; Stivers Y; Cicero TJ
J Opioid Manag; 2009; 5(2):81-7. PubMed ID: 19507804
[TBL] [Abstract][Full Text] [Related]
10. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison.
Hughes AA; Bogdan GM; Dart RC
Clin Toxicol (Phila); 2007; 45(2):144-51. PubMed ID: 17364631
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective.
Manchikanti L; Fellows B; Ailinani H; Pampati V
Pain Physician; 2010; 13(5):401-35. PubMed ID: 20859312
[TBL] [Abstract][Full Text] [Related]
12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
13. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
[TBL] [Abstract][Full Text] [Related]
14. Substance use histories in patients seeking treatment for controlled-release oxycodone dependence.
Potter JS; Hennessy G; Borrow JA; Greenfield SF; Weiss RD
Drug Alcohol Depend; 2004 Nov; 76(2):213-5. PubMed ID: 15488345
[TBL] [Abstract][Full Text] [Related]
15. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
Zacny JP; Gutierrez S
Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
[TBL] [Abstract][Full Text] [Related]
16. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
17. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
[TBL] [Abstract][Full Text] [Related]
18. Detecting signals of opioid analgesic abuse: application of a spatial mixed effect poisson regression model using data from a network of poison control centers.
Smith MY; Irish W; Wang J; Haddox JD; Dart RC
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1050-9. PubMed ID: 18803336
[TBL] [Abstract][Full Text] [Related]
19. Trends in opioid analgesic abuse and mortality in the United States.
Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
[TBL] [Abstract][Full Text] [Related]
20. Monitoring risk: post marketing surveillance and signal detection.
Dart RC
Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
